Mark Shuhkman, MD and Andrey Lev-Weissberg, MD - Psychiatric Disorders (2013 Conference) (LDN, low dose naltrexone)

Dr Mark Shukhman - LDN in Psychiatry (2014 Conference) (LDN, low dose naltrexone)

Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial

Trials
15 November 2021
https://pubmed.ncbi.nlm.nih.gov/34781989/

The EMF Toxicity Epidemic - Protection and Treatment - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Longevity - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Hypothyroidism - Dawn Ipsen, PharmD (2021 Conference) (LDN, low dose naltrexone)

Dr. Dawn Ipsen is a compounding pharmacist who presents on some roles low dose naltrexone (LDN) may have in helping patients with hypothyroidism. She discusses hypothyroidism, its prevalence, and treatment goals. 

Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)